SML3975
Ponesimod

≥95% (HPLC)
동의어(들):
(2Z,5Z)-5-[3-Chloro-4-[(2R)-2,3dihydroxypropoxy ]benzylidene ]-3-(2-methylphenyl)-2-(propylimino )-1,3-thiazolidin-4-one, (R)-5-[3-Chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, 5-[3-Chloro-4-((2R)-2,3-dihydroxy-propoxy)-benz-(Z)-ylidene]-2-[(Z)-propylimino]-3-o-tolyl-thiazolidin-4-one, ACT 128800, ACT-128800, ACT128800
About This Item
추천 제품
Quality Level
분석
≥95% (HPLC)
양식
powder
색상
white to beige
solubility
DMSO: 2 mg/mL, clear
저장 온도
-10 to -25°C
SMILES string
S1\C(=N/CCC)\N(C(=O)\C\1=C\c3cc(c(cc3)OC[C@H](O)CO)Cl)c2c(cccc2)C
InChI
1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1
InChI key
LPAUOXUZGSBGDU-STDDISTJSA-N
생화학적/생리학적 작용
Ponesimod (ACT-128800) is an orally active, potent and subtype-selective sphingosine-1-phosphate (S1P) receptor agonist (human S1P1/2/3/4/5 EC50 = 5.7 nM/>10 µM/105 nM/1.108 µM/59.1 nM by 35S-GTPγ binding, 6.0 nM/>10 µM/2.068 µM/1.956 µM/142 nM by 33P-S1P binding). Ponesimod oral administration causes a significant decrease in peripheral lymphocyte counts in rats in vivo (by 65-75% 3h post 3 mg/kg).
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.